Skip to content Skip to sidebar Skip to footer

Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint

Rebound gains fuel as FDA orphan tag backs 38-patient efti data Immutep (ASX:IMM) has received FDA orphan drug designation for eftilagimod alfa, or efti, in soft tissue sarcoma. This is…

ByCharlie Youlden

Apr 2026

Biotech Stocks Growth Stocks Healthcare Stocks Life Sciences Mid Cap Stocks Small Caps Stocks

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the…

ByNick Sundich

Mar 2026

Biotech Stocks Healthcare Stocks Life Sciences

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with…

ByNick Sundich

Feb 2026

Healthcare Stocks

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks Technology

Immutep (ASX:IMM) Surges on US$369M Global Partnership With Dr. Reddy’s

Immutep Lands Global Deal With Dr. Reddy’s Immutep (ASX:IMM) surged 23% at market open after announcing a new strategic partnership through a collaboration and licensing agreement with Dr Reddys Laboratories,…

ByCharlie Youlden

Jun 2025

Small Caps Stocks

6 ASX Small Cap Stocks to Watch in June 2025

Let's take a look at 6 ASX small cap stocks to watch! ASX small cap stocks, we mean companies with a market capitalisation between $50 million and $500 million. We acknowledge…

ByUjjwal Maheshwari

May 2025

Healthcare Stocks

Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027

Developing a cancer drug is a long journey, but Immutep (ASX:IMM) is more towards the end than the start. A few months ago, when it received its latest capital injection…

ByNick Sundich

Nov 2022

Life Sciences Tech Stocks

Immutep (ASX: IMM) has massive potential!

Immutep ( ASX: IMM ) develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has several product candidates at different phases of clinical trials. But its…